Transgene shares surge 20% on positive Phase 1 head-and-neck cancer vaccine data
Transgene EURONEXT:TNG shares jumped 20% in early Paris trading after the French biotech reported positive Phase 1 trial data on its head-and-neck cancer vaccine candidate.
Transgene EURONEXT:TNG shares surged 20% in early Paris trading on Thursday, after the French biotechnology company reported positive Phase 1 trial data on its vaccine candidate for head and neck cancer.Investors have rewarded encouraging data from other personalised cancer-vaccine programmes as we…